|
Re: General360
|
5
|
Resverlogix Corp.
|
Jun 21, 2017 03:52PM
|
|
Re: General360
|
1
|
Resverlogix Corp.
|
Jun 21, 2017 04:43PM
|
|
Re: BetOnMace, US inclusion
|
1
|
Resverlogix Corp.
|
Jun 21, 2017 10:15PM
|
|
Re: BetOnMace, US inclusion
|
3
|
Resverlogix Corp.
|
Jun 22, 2017 10:47AM
|
|
Novartis Phase III study shows Canakinumab reduces MACE events
|
5
|
Resverlogix Corp.
|
Jun 22, 2017 11:19AM
|
|
Re: biOasis to present at Global Chinese Financial Forum – Shanghai Conference 2017
|
1
|
BIOASIS TECHNOLOGIES INC
|
Jun 22, 2017 11:26AM
|
|
Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
5
|
Resverlogix Corp.
|
Jun 22, 2017 11:46AM
|
|
PCSK9 vaccination
|
5
|
Resverlogix Corp.
|
Jun 22, 2017 12:40PM
|
|
Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
4
|
Resverlogix Corp.
|
Jun 22, 2017 01:06PM
|
|
Re: Managing Diabetes & CVD: Is epigenetics a new way forward?
|
3
|
Resverlogix Corp.
|
Jun 23, 2017 10:51AM
|
|
Re: BET inhibition in renal and cardiovascular disease: What is the clinical roadmap? VIDEO
|
2
|
Resverlogix Corp.
|
Jun 23, 2017 10:57AM
|
|
Re: Managing Diabetes & CVD: Is epigenetics a new way forward?
|
3
|
Resverlogix Corp.
|
Jun 23, 2017 01:39PM
|
|
Re: What happens if.....
|
4
|
Resverlogix Corp.
|
Jun 25, 2017 11:33PM
|
|
biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations
|
|
BIOASIS TECHNOLOGIES INC
|
Jun 26, 2017 10:33AM
|
|
Re: What happens if.....
|
3
|
Resverlogix Corp.
|
Jun 26, 2017 10:40AM
|
|
Merck lands positive PhIII for its CETP drug anacetrapib
|
1
|
Resverlogix Corp.
|
Jun 27, 2017 08:42AM
|
|
Re: BETonMACE Enrollment
|
4
|
Resverlogix Corp.
|
Jun 28, 2017 10:37AM
|
|
Re: Nice volume surge at the end....
|
4
|
Resverlogix Corp.
|
Jun 28, 2017 10:45AM
|
|
Re: Nice volume surge at the end....
|
3
|
Resverlogix Corp.
|
Jun 28, 2017 11:35AM
|
|
Re: Nice volume surge at the end....
|
2
|
Resverlogix Corp.
|
Jun 28, 2017 12:17PM
|
